Gabriela M. Pavlasova

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib.

Journal: Haematologica
Published: February 25, 2021

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Journal: Blood
Published: March 11, 2020

The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.

The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.

Journal: Haematologica
Published: November 22, 2019

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

Journal: Blood
Published: June 10, 2018

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.

MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.

Journal: Leukemia
Published: April 25, 2018

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.

Journal: Leukemia
Published: February 02, 2018

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Journal: Blood
Published: April 05, 2016

DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.

DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.

Journal: Oncology reports
Published: November 19, 2014

New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells.

New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: January 01, 2012
Showing 1-9 of 9

Last Updated: 09/26/2026